Cargando…
Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature
A 45-year-old woman with a history of lung adenocarcinoma treated with osimertinib developed purpuric plaques and vesicles on the lower extremities after 5 months of therapy. Skin biopsy revealed leukocytoclastic vasculitis (LCV). A workup for systemic involvement was unremarkable. The patient was t...
Autores principales: | Iriarte, Christopher, Young, Jonathan H., Rabin, Michael S., LeBoeuf, Nicole R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579488/ https://www.ncbi.nlm.nih.gov/pubmed/36275908 http://dx.doi.org/10.1016/j.jtocrr.2022.100415 |
Ejemplares similares
-
Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression
por: Bui, Ai-Tram N., et al.
Publicado: (2020) -
Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature
por: Song, Johanna S., et al.
Publicado: (2017) -
Treatment-refractory cutaneous Rosai–Dorfman disease responsive to oral methotrexate and topical trametinib
por: Fay, Christopher J., et al.
Publicado: (2023) -
Treatment of refractory IgA vasculitis with dapsone: a systematic review
por: Lee, Keum Hwa, et al.
Publicado: (2019) -
Dapsone: a steroid-sparing drug for refractory immunoglobulin A vasculitis?
por: Suh, Jin-Soon
Publicado: (2020)